Gregory Russotti Sells Shares of Century Therapeutics

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (NasdaqCM: IPSC), sold 2,584 shares of the company on June 12, 2026. The shares were sold at an average price of $2.23 each, bringing the total value of the transaction to $5,762. This transaction was not part of a planned sale.

Insider Buying and Selling at Century Therapeutics, Inc.

On June 12, 2026, Gregory Russotti sold 2,584 shares of Century Therapeutics, while Douglas Carr, SVP Finance & Operations, also sold 1,654 shares at $2.23 each. Additionally, on June 11, 2026, Brent Pfeiffenberger, the President and CEO, sold 13,849 shares at $2.24 each. Chad Cowan, Chief Scientific Officer, sold 358 shares at the same price. In contrast, insiders Han Myung Lee and Daphne Quimi each bought 74,000 shares on June 11, 2026.

Other Institutional Activity in Century Therapeutics

Several institutional investors have shown interest in Century Therapeutics. Versant Venture Management, LLC added 24,332,218 shares, ending with a total of 24,332,218 shares valued at approximately $54.99 million. TCG Crossover Management, LLC and RA Capital Management, L.P. both increased their holdings by 17,754,430 shares each, bringing their totals to 17,754,430 shares worth about $39.02 million and $40.13 million, respectively. Deep Track Capital, LP added 9,487,745 shares, with a total value of $21.44 million, and RTW Investments, LP increased its stake by 8,695,652 shares, holding a total worth $19.65 million.

Century Therapeutics Stock Snapshot

Shares of Century Therapeutics, Inc. (NasdaqCM: IPSC) traded near $2.25. The company has a market capitalization of approximately $405.8 million and a forward P/E ratio of -4.92, indicating it is not currently profitable. The stock's beta is 1.566, suggesting it is more volatile than the market. Over the last 52 weeks, the stock has traded between $0.435 and $3.04. Its 50-day moving average is $2.28, while the 200-day moving average stands at $1.48. The company maintains a strong liquidity position with a current ratio of 10.25 and a quick ratio of 10.04. Its debt-to-equity ratio is 18.14.

Analysts Set New Price Targets

On May 27, 2026, Mizuho initiated coverage of Century Therapeutics with a 'buy' rating and an $8.00 price target. HC Wainwright & Co. maintained its 'buy' rating on April 21, 2026, with a target price of $5.00. Piper Sandler also maintained a 'buy' rating with a $4.00 target on January 20, 2026. The consensus recommendation is a 'buy', with a mean target price of $4.75 based on four analyst opinions.

About Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company based in Philadelphia, Pennsylvania. It focuses on developing allogeneic cell therapies to treat solid tumors, hematological cancers, and autoimmune diseases. The company's leading product candidate is CNTY-813, designed for type 1 diabetes treatment. Other projects include CNTY-308, targeting B-cell-mediated autoimmune diseases, and CNTY-101, aimed at CD19-related conditions. Led by CEO Dr. Brent Pfeiffenberger, the company employs about 78 people.

Bottom Line

Gregory Russotti's recent sale of Century Therapeutics shares is a notable insider transaction. Investors keep an eye on such moves for insights into insider sentiment. Century Therapeutics continues to attract institutional interest, with several funds increasing their stakes. Analyst coverage remains positive, with a consensus 'buy' rating and a target price of $4.75. As always, remember that insider sales and institutional holdings can be backward-looking indicators.